Protalix BioTherapeutics, Inc.
PLXAMEXHealthcare● Active
$1.96
$-0.03(-1.51%)
Market Cap$157920418
P/E Ratio—
52W High$3.19
52W Low$1.32
Protalix BioTherapeutics, Inc. (PLX) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PLX · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($6.60M) | $2.93M | $8.31M | ($14.93M) | ($27.58M) |
| Depreciation & Amort. | $0.00M | $1.30M | $1.19M | $1.09M | $1.12M |
| Stock-Based Comp. | $0.00M | $3.25M | $3.45M | $2.08M | $2.38M |
| Change in Working Capital | ($10.10M) | $0.81M | ($10.54M) | ($12.02M) | $9.90M |
| Net Cash from Operations | ($11.99M) | $8.67M | ($1.32M) | ($25.00M) | ($10.29M) |
| Investing Activities | |||||
| Capital Expenditure | ($1.64M) | ($1.28M) | ($1.15M) | ($0.63M) | ($1.46M) |
| Purchases of Investments | $0.00M | ($15.00M) | ($20.42M) | ($16.00M) | ($37.84M) |
| Sales of Investments | $0.00M | $20.42M | $5.00M | $11.00M | $57.84M |
| Net Cash from Investing | ($2.37M) | $4.22M | ($16.71M) | ($5.04M) | $18.92M |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | ($20.42M) | $0.00M | $0.00M | ($34.12M) |
| Net Cash from Financing | $9.33M | ($16.79M) | $24.67M | $8.24M | $12.08M |
| Free Cash Flow | |||||
| Free Cash Flow | ($13.63M) | $7.39M | ($2.47M) | ($25.63M) | ($11.74M) |
| FCF Margin %(computed) | -25.84% | 13.84% | -3.77% | -53.80% | -30.62% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more Protalix BioTherapeutics, Inc. data
About Protalix BioTherapeutics, Inc. (PLX) Cash Flow Statement
Protalix BioTherapeutics, Inc. generated operating cash flow of ($0.01B) and free cash flow of ($0.01B) for 2025 — a FCF margin of -25.84%. Capital expenditure was ($0.00B).
Frequently asked questions
PLX · 4 questionsProtalix BioTherapeutics, Inc. generated free cash flow of ($0.01B) for 2025, down 284.4% year-over-year.
PLX free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10